telbivudine: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
telbivudine: clinical details
Prescribing considerations
- The selected product is discontinued; confirm availability and current specialist treatment plans.
- Initiation requires chronic-hepatitis-B expertise, with preference for an appropriate antiviral having a higher genetic barrier to resistance.
- Limited evidence applies to cirrhosis; adequate evidence is lacking in decompensated cirrhosis, transplant recipients and HBV coinfection.
- Telbivudine monotherapy is unsuitable for established lamivudine-resistant HBV, and resistance testing should inform loss of response.
- Safety and efficacy have not been established in children.
Contraindications and cautions
- Hypersensitivity to telbivudine or an excipient
- Concurrent standard or pegylated interferon alfa
Monitoring
- HBV DNA and biochemical response, with resistance assessment if suppression is incomplete or viral breakthrough occurs
- Liver function during treatment and after withdrawal because severe post-treatment flares can occur
- Renal function because unchanged telbivudine is principally cleared in urine
- Muscle symptoms and creatine kinase when clinically indicated
- Symptoms of peripheral neuropathy
Clinical pharmacology
A synthetic thymidine nucleoside analogue activated intracellularly to telbivudine triphosphate. It inhibits HBV DNA polymerase through substrate competition and viral DNA-chain termination. Protein binding is low, CYP-mediated interaction potential is low, and elimination is mainly renal as unchanged telbivudine.
Formulation and product differences
- The selected presentation was a film-coated tablet that must not be chewed, split or crushed.
- The SmPC also referred to an oral solution for swallowing difficulty and renal-adjustment requirements, but this was not the selected presentation.
telbivudine interactions
Tell the prescriber and pharmacist about all medicines. Important examples include:
Standard or pegylated interferon alfa
This combination is contraindicated because it substantially increases the risk of peripheral neuropathy.
Medicines affecting kidney function, including aminoglycosides, loop diuretics, platinum compounds, vancomycin and amphotericin B
They may alter telbivudine or co-administered medicine concentrations, requiring caution and monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.